aptaTargets
@AptaTargets
Followers
142
Following
233
Media
78
Statuses
200
Pioneering therapies based on #aptamer technology
Madrid (Spain)
Joined January 2022
We are excited to announce an agreement with @MerckHealthcare for the clinical development and commercialization of #ApTOLL, a Toll-like receptor 4 (TLR4) antagonist being developed for acute ischemic stroke. Learn more: https://t.co/MXscgFtEyv
#healthcare #innovation
0
5
14
🌟 aptaTargets and @merckgroup named finalists in 2025 European @lifestarsawards for transfer of neuroprotective drug #ApTOLL 🌟 Learn more on our website: https://t.co/7ii7Vxi4M1
#lifestarsawards
0
0
1
#ApTOLL’s secondary analysis data of APRIL 1b/2a trial published in scientific journal “Stroke” from @American_Heart: https://t.co/NCtGF3BKtZ
#stroke #AcuteIschemicStroke #cerebroprotection
0
2
6
#Investigación | ➡️El emprendimiento en el ámbito biomédico va acompañado de algunas metas a superar específicas de este sector. ➡David Segarra, CEO de @AptaTargets, cuenta los obstáculos a superar en el escalado de la innovación en este sector.
diariomedico.com
Plazos impredecibles, producción compleja, falta apoyo tractor de la innovación y dificultades para encontrar inversores son algunos retos del escalado de la innovación biomédica.
0
1
2
#Investigación | ➡️El emprendimiento en el ámbito biomédico va acompañado de algunas metas a superar específicas de este sector. ➡David Segarra, CEO de @AptaTargets, cuenta los obstáculos a superar en el escalado de la innovación en este sector.
diariomedico.com
Plazos impredecibles, producción compleja, falta apoyo tractor de la innovación y dificultades para encontrar inversores son algunos retos del escalado de la innovación biomédica.
0
1
2
.@inveready has achieved a 4x return on its Innvierte Biotech II fund. Benchmark Spanish financial newspaper @expansioncom highlights aptaTargets among its top investments. aptaTargets recently transferred its drug #ApTOLL to @merckgroup.
1
0
2
.@AptaTargets has announced an agreement with German pharmaceutical giant @Merck for the clinical development and commercialisation of ApTOLL, a TLR4 antagonist being developed to treat acute ischaemic #Stroke
https://t.co/GnAe84K956
neuronewsinternational.com
AptaTargets has announced an agreement with German pharmaceutical giant Merck—signed in October 2024—for the clinical development and commercialisation of ApTOLL, a Toll-like receptor 4 (TLR4)...
0
1
3
1
1
5
⚕️Today on #WorldHealthDay, we're highlighting three top #eicBAS beneficiaries driving better #HealthForAll and #HopefulFutures globally: 💡 @SymphysisMed 🧠 @AptaTargets 🩺 Better Medicine Check them out 👉 https://t.co/OQeGyQChaX
4
1
7
A new study shows the cerebroprotective effects of #ApTOLL on mice with #AcuteIschemicStroke: https://t.co/2grZgxOa6E The study, published in "Pharmaceutics" (@MDPIpharma), was conducted by researchers at aptaTargets (Dr. Macarena Hernández) and @IISLaFe (Dr. Juan Salom).
0
0
5
Preclinical studies validate the potential of #ApTOLL developed by aptaTargets to reduce inflammation and regenerate myelin in models of #MultipleSclerosis. Results published in @BrJPharmacol: https://t.co/qn7V8XsFD1
0
4
5
Today our Clinical Operations Manager @MarcoPugliese7 will speak at "Creative strategies to accelerate patient recruitment rate during study planning" in Barcelona. With Alicia Rami @Fortrea, @Estrell67715016 (Almirall), Núria Bordas @ferrerforgood and Joseph Lovett @Medidata 👇🏼
0
1
2
There's still time to register for #ESOC2024 in Basel, starting in just a week! 📅 https://t.co/uv35RHTdXa Get ready to hear from leading experts, engage in innovative discussions, and be part of the latest advancements in stroke research. #stroke #voiceofstroke #stroketwitter
0
6
18
Our CSO Macarena Hernández (@makimhj) will speak at the 10th European #Stroke Conference next May 15 in Basel. Join us to discover “Tackling the Inflammation: The #APRIL group”. 🕓 3:50 pm 📍 Basel - Room Boston ℹ️ https://t.co/gMGsogpK1z
#ESOC2024 #ApTOLL #cytoprotection
0
3
6
We are thrilled to announce that over 1,000 companies in Europe, aptaTargets was selected for the #EICAccelerator by @EUeic. It secures €2.5M grant to start the Phase 2b clinical trial with #ApTOLL in patients with #AcuteIschemicStroke: https://t.co/kPy7tuFviG
0
1
3
Proximo miercoles en el @USPCEU hablaré sobre los #aptameros y sus aplicaciones. Desde @AptaTargets trabajamos en el consorcio @oligofastx en el tratamiento de #EnfermedadesRaras como el Síndrome de Guillain-Barré
0
2
3
El próximo miércoles 6 de marzo recibiremos a Miguel Moreno Molina, de @AptaTargets, en nuestros seminarios de la @USPCEU . Conoceremos los últimos avances en tecnología de aptámeros. Bienvenido!
1
1
3
aptaTargets, that has obtained the Seal of Excellence 🏅 from the #EICAccelerator, has been selected by the @ComunidadMadrid to receive a direct grant of €1.940M: https://t.co/ZAfDi4QTsF
#ApTOLL #neuroprotection #AcuteIschemicStroke #EUeic #HorizonEurope #NextGenerationEU
0
0
5
🧪 #OLIGOFASTX has the leading experts in each field in the area of oligonucleotide research who can provide solutions in the research of new therapies against rare diseases. 🧬 📌 https://t.co/MFJcXN1kam
#fundedbyCDTI
0
1
1